-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
May 8, 2020 / Biovalley BIOON / -- The findings of a new study led by Professor Xu Guowang of the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences have shed light on selective therapy for glioblastoma with a mutation in the targetglutic glutamate synthesis approach to treatithibuttirate i (Iocitit dehydrogenae I, IDH1) study was published in PNAS Glioma is the most common primary brain tumor The IDH1 mutation is a cancer-related mutation that is common in glioma patients the source of the images; DPIC Although the carcinogenic effects of the IDH1 mutation have been demonstrated in several solid tumors, there is a lack of selective treatment for malignant tumor
s of the IDH1 mutation researchers have shown that glutathione from scratch plays an important role in the cells of the IDH1 mutation The synthesis of glutathione is controlled by the transcription factor Nrf2, which regulates the gene expression of antioxidant pathways Professor said: "Our in vitro studies have shown that the disruption of the Nrf2-driven glutathione synthesis pathway is collaborativeally fatal with the new form of the IDH1 mutation "
rekradomin is a ditrian epoxy compound from Leigong, an effective Nrf2 inhibitor Rekotomethin is selectively cytotoxic to the glioma cells of the IDH1 mutation of the body and in vitro patients In addition, we also studied the anti-cancer mechanism of Rexion mechanism, rex ontomethyline prevents the expression of GCLC, GCLM, and SLC7A11, thus disrupting the metabolism of glutathione and leading to synthetic death along with reactive oxygen (ROS) produced by the new form activity of the IDH1 mutants the study highlights that rekradoisin is a valuable treatment for malignant tumor of the IDH1 mutation through a targeted Nrf2-driven glutathione synthesis pathway (BioValleyBioon.com) References: New he findd light on elective therapeutic for IDH1-declaration-dema
Di Yu el al., "
Triptolide uppree IDH1-stateade encivien enbyn cynr, " PNAS (2020 http:// 1073/pna.1913633117
